Eli Lilly's Stock Surges While Novo Nordisk's Sinks Amid Diverging Weight-Loss Strategies

Eli Lilly's stock surged 10% on stronger-than-expected earnings, while Novo Nordisk's shares sank 6% after the Danish drugmaker warned of slowing sales due to lower U.S. prices, less Medicaid coverage, and increased competition. The divergence between the shares has widened since last fall, with Eli Lilly's stock rising 33% in the last 12 months and Novo Nordisk's shares dropping 40%.